Valneva SE
Company Profile
Business description
Valneva SE is a vaccine company focused on developing life-saving vaccines. Its portfolio includes three vaccines for travelers. The segments of the group are Commercialized vaccines which relate to marketed vaccines, the group's vaccines IXIARO/JESPECT, DUKORAL, IXCHIQ; Covid includes development, manufacturing, & distribution related to the COVID-19 vaccine, Vaccine candidates which relate to research and development programs to generate new approvable products to generate future cash flows from product sales through partnering with pharmaceutical companies; & Technologies and services which relate to services and inventions at a commercialization stage. The company generates majority of its revenue from product sales.
Contact
6 Rue Alain Bombard
Saint-Herblain44800
FRAT: +33 228073710
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
713
Stocks News & Analysis
stocks
Impact of ANZ’s huge fine
stocks
Acquisition a sign of weakness for overvalued ASX share
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
---|---|---|---|
All Ordinaries | 9,120.90 | 34.10 | 0.38% |
CAC 40 | 7,896.93 | 71.69 | 0.92% |
DAX 40 | 23,748.86 | 50.71 | 0.21% |
Dow JONES (US) | 45,883.45 | 49.23 | 0.11% |
FTSE 100 | 9,277.03 | 6.26 | -0.07% |
HKSE | 26,446.56 | 58.40 | 0.22% |
NASDAQ | 22,348.75 | 207.64 | 0.94% |
Nikkei 225 | 44,768.12 | 395.62 | 0.89% |
NZX 50 Index | 13,208.31 | 19.59 | -0.15% |
S&P 500 | 6,615.28 | 30.99 | 0.47% |
S&P/ASX 200 | 8,853.00 | 31.60 | 0.36% |
SSE Composite Index | 3,860.50 | 10.09 | -0.26% |